Verve Therapeutics, Inc. (VERV) Tops Q3 EPS by 18c

Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q3 EPS of ($0.72), $0.18 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $3.12 million versus the consensus estimate of $963.67 thousand.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• CoStar Group acquires Zonda for $800M, adding new home data